The Patent Finder

Nymox Corporation

Also on record
Records under this name other than the patents Nymox Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 7 patents it holds.

Back to Nymox Corporation

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 11,331,374Focal treatment of prostate cancer
Lapsed on the fee record
Ended May 17, 2026 · USPTO record
Lapsed on the fee recordEnded May 17, 2026USPTO record
US 8,716,247Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
Lapsed on the fee record
Ended May 6, 2026 · USPTO record
Lapsed on the fee recordEnded May 6, 2026USPTO record
US 11,298,400Method of Enhancing the Therapeutic Efficacy of Fexapotide Triflutate in Treating Luts
Lapsed on the fee record
Ended Apr 12, 2026 · Medium confidence
Lapsed on the fee recordEnded Apr 12, 2026Medium confidence
US 11,278,588Method of Treating Lower Urinary Tract Symptoms with Fexapotide Triflutate
Lapsed on the fee record
Ended Mar 22, 2026 · Medium confidence
Lapsed on the fee recordEnded Mar 22, 2026Medium confidence
US 11,231,421Methods of Treating Multifocal Cancer
Lapsed on the fee record
Ended Jan 25, 2026 · Medium confidence
Lapsed on the fee recordEnded Jan 25, 2026Medium confidence
US 10,835,538Method of treating benign prostatic hyperlasia with antibiotics
Lapsed on the fee record
Ended Nov 17, 2024 · USPTO record
Lapsed on the fee recordEnded Nov 17, 2024USPTO record
US 7,514,407Spheron component peptides and pharmaceutical compositions
Term ended
Term ended May 30, 2024 · USPTO record
Term endedTerm ended May 30, 2024USPTO record
US 7,408,021Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
Term ended
Term ended Mar 7, 2024 · USPTO record
Term endedTerm ended Mar 7, 2024USPTO record
US 9,243,035Peptides effective in the treatment of conditions requiring the removal or destruction of cells
Lapsed on the fee record
Ended Jan 26, 2024 · USPTO record
Lapsed on the fee recordEnded Jan 26, 2024USPTO record
US 10,532,081Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
Lapsed on the fee record
Ended Jan 14, 2024 · USPTO record
Lapsed on the fee recordEnded Jan 14, 2024USPTO record
10 of 27 patents shown.
Pro members see all 27.
Pro members: see all 27 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited